greeksoup/ stock research

Arrowhead Pharmaceuticals (ARWR) FY2011 results: revenue $296,139

Arrowhead Pharmaceuticals, Inc. (ARWR) reported revenue of $296,139 for fiscal 2011, the year ended 30 September 2011. Net income was -$3 million, and diluted earnings per share $-0.40. The figures are the company's own, from the 10-K it filed with the SEC on 20 December 2011.

Revenue
$296,139
FY2011FY2011
Operating margin
-3319.5%
FY2011FY2011
Net income
-$3 million
FY2011FY2011
Diluted EPS
-$0.40
FY2011FY2011

this yearthe year beforeHover a bar for its figure.

The year in brief

Income statement (profit and loss)

$ millionFY2011Last 8 years
Revenue0.3
Research and development3.3
Operating income-9.8
Operating margin-3319.5%
Pre-tax income-8.8
Net income-3.1
Net margin-1056.6%
Diluted EPS-$0.40
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionFY2011Last 8 years
Operating cash flow-5.4
Capital expenditure0.0
Free cash flow-5.4
Free cash flow margin-1823.6%
Depreciation and amortisation0.3
Share-based compensation1.4
Diluted shares, weighted8m
Shares outstanding at period end9m

Balance sheet

$ millionFY2011Last 8 years
Shareholders' equity12.8
Non-controlling interest-0.2
Debt0.6
Other liabilities2.7
Total liabilities and equity15.9
Fixed assets0.0
Intangible assets1.7
Investments0.6
Cash and equivalents7.5
Other assets6.0
Total assets15.9

10-K for the year ended 30 September 2011, filed 20 December 2011: the filing.